Results from the Phase 1b dose escalation of the TheraPb clinical trial (NCT05720130) presented at the European Society for Medical Oncology (ESMO) 2025 congress on October 18, 2025.
Results from the Phase 1b dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer: The TheraPb trial
